Alopecia Areata
Symptoms, Doctors, Treatments, Advances & More

Learn About Alopecia Areata

What is the definition of Alopecia Areata?

Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition.

What are the causes of Alopecia Areata?

The causes of alopecia areata are complex and not well understood. A combination of factors likely underlies the disorder, including changes in many genes that function in the hair and skin and in the immune system.

How prevalent is Alopecia Areata?

Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia; alopecia areata is the second most common form after androgenetic alopecia (male-pattern baldness in men and female-pattern baldness in women). Alopecia areata affects men and women equally, and it can occur in people of any ethnic background.

Is Alopecia Areata an inherited disorder?

The inheritance pattern of alopecia areata is unclear because multiple genetic and environmental factors appear to be involved. Overall, the risk of developing the condition is greater for first-degree relatives (such as siblings or children) of affected individuals than it is in the general population. People with alopecia areata are also more likely to have family members with other autoimmune disorders.

Who are the top Alopecia Areata Local Doctors?
Elite in Alopecia Areata
Dermatology | Internal Medicine
Elite in Alopecia Areata
Dermatology | Internal Medicine
221 Longwood Ave, 
Boston, MA 
Languages Spoken:
English
Offers Telehealth

Arash Mostaghimi is a Dermatologist and an Internal Medicine provider practicing medicine in Boston, Massachusetts. Dr. Mostaghimi is rated as an Elite provider by MediFind in the treatment of Alopecia Areata. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Alopecia Areata, Autosomal Recessive Hypotrichosis, Pyoderma Gangrenosum, and Cellulitis. Dr. Mostaghimi is board certified in Dermatology, Internal Medicine, and Clinical Informatics.

Elite in Alopecia Areata
Dermatology
Elite in Alopecia Areata
Dermatology
33100 Cleveland Clinic Blvd, 
Avon, OH 
Experience:
66+ years
Languages Spoken:
English
Offers Telehealth

Wilma Bergfeld is a Dermatologist practicing medicine in Avon, Ohio. She has been practicing medicine for over 66 years. Dr. Bergfeld is rated as an Elite provider by MediFind in the treatment of Alopecia Areata. She is also highly rated in 74 other conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Graham-Little-Piccardi-Lassueur Syndrome, Alopecia Areata, Squamous Cell Skin Carcinoma, and Osteotomy. Dr. Bergfeld is board certified in American Board Of Dermatology, 1974.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Alopecia Areata
Elite in Alopecia Areata
516 Delaware St Se # 1, 
Minneapolis, MN 
Languages Spoken:
English
Offers Telehealth

Maria Hordinsky is a Dermatologist practicing medicine in Minneapolis, Minnesota. Dr. Hordinsky is rated as an Elite provider by MediFind in the treatment of Alopecia Areata. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Alopecia Areata, Graham-Little-Piccardi-Lassueur Syndrome, and Alopecia Universalis.

What are the latest Alopecia Areata Clinical Trials?
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata

Summary: The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

Summary: The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss. This study is seeking participants who have: * at least 50% scalp hair loss due to alopecia areata. * received varicella vaccination (2 doses) or have been infected by varicella zos...

Who are the sources who wrote this article ?

Published Date: June 01, 2018
Published By: National Institutes of Health